SecurityTGXSF / Tigenix Sa
InstitutionGrifols SA
Shares39,427,978
Ownership 14.40%

Grifols SA discloses 14.40% activist ownership in TGXSF / Tigenix Sa

January 08, 2018 - Grifols SA has filed an SC 13D form with the Securities and Exchange Commission (SEC) disclosing ownership of 39,427,978 shares of Tigenix Sa (OTC:TGXSF). This represents 14.4 percent ownership of the company. In their previous filing dated July 13, 2017, Grifols SA had reported owning 9,073,538 shares, indicating an increase of 334.54 percent.

13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date
Effective
Date
Form Prev
Shares
Reported
Shares
Change in Shares
(Percent)
Ownership
(Percent)
Change in Ownership
(Percent)
2018-01-08 2018-01-08 SC 13D 9,073,538 39,427,978 334.54 14.40 -70.19
2017-07-13 2017-07-13 SC 13G 41,929,954 16.10

Related SEC Filings

TGXSF / Tigenix Sa / Cormorant Asset Management, LLC - 3G/A (Passive Investment)

2018-02-16 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549       SCHEDULE 13G       Under the Securities Exchange Act of 1934       (Amendment No. 2)*     TiGenix NV     (Name of Issuer)     Ordinary Shares, no par value per share     (Title of Class of Securities)     88675R109     (CUSIP Number)     December 31, 2017     (Date of Event which Requires Filing of this Statement)   Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ]           

TGXSF / Tigenix Sa / Cormorant Asset Management, LLC - 3G/A (Passive Investment)

2018-02-16 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549       SCHEDULE 13G       Under the Securities Exchange Act of 1934       (Amendment No. 2)*     TiGenix NV     (Name of Issuer)     Ordinary Shares, no par value per share     (Title of Class of Securities)     88675R109     (CUSIP Number)     December 31, 2017     (Date of Event which Requires Filing of this Statement)   Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ]           

TGXSF / Tigenix Sa / TAKEDA PHARMACEUTICAL CO LTD - SC 13D (Activist Investment)

2018-01-12 sec.gov
SC 13D     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.     )*     TiGenix (Name of Issuer) Ordinary shares, no nominal value (“Shares”) American Depositary Shares (“ADSs”), each representing 20 Shares (Title of Class of Securities) ISIN BE0003864817 (Shares) CUSIP 88675R109 (ADSs) (CUSIP Number) James Kehoe Takeda Pharmaceutical Company Limited 12-10, Nihonbashi 2-Chome, Chuo-ku, Tokyo 103-8668

TGXSF / Tigenix Sa / TAKEDA PHARMACEUTICAL CO LTD - SC 13D (Activist Investment)

2018-01-12 sec.gov
SC 13D     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.     )*     TiGenix (Name of Issuer) Ordinary shares, no nominal value (“Shares”) American Depositary Shares (“ADSs”), each representing 20 Shares (Title of Class of Securities) ISIN BE0003864817 (Shares) CUSIP 88675R109 (ADSs) (CUSIP Number) James Kehoe Takeda Pharmaceutical Company Limited 12-10, Nihonbashi 2-Chome, Chuo-ku, Tokyo 103-8668

Tigenix SCHEDULE 13G (Passive Acquisition of More Than 5% of Shares)

2017-07-13 sec.gov
Schedule 13G     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.    )*     TiGenix   (Name of Issuer)         ordinary shares, no nominal value per share         (Title of Class of Securities)                 88675R 10 9                 (CUSIP Number)                 December 20, 2016                 (Date of Event Which Requires Filing of this Statement)     Check the appropriate box to designate t

Related News Stories

Takeda Announces Information Related to its Pending Voluntary and Conditional Public Takeover Bid for Outstanding Shares and American Depositary Shares of TiGenix | Business Wire

2018-05-23 businesswire
OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) today announced information related to its previously announced and ongoing tender offer (the “Bid”) in cash for all outstanding ordinary shares (“Ordinary Shares”), warrants (“Warrants”) and American Depositary Shares (“ADSs”) of TiGenix NV (Euronext Brussels and NASDAQ: TIG) (“TiGenix”) that are not yet owned by Takeda and its affiliates, in two separate, but concurrent and related offers in Belgium (the “Belgian Offer”) and in the United States (the “U.

Shire bid marks Takeda’s latest and biggest push for global status

2018-04-26 japantimes.co.jp
Takeda Pharmaceutical Co. Ltd..’s $64 billion bid for London-listed rare-disease specialist Shire PLC bolsters its credentials as Japan’s most outward-facing drugs firm, a mold-breaking image that has been more than a decade in the making. (3-0)

Shire bid marks Takeda's latest - and biggest - push for global status

2018-04-25 reuters
TOKYO (Reuters) - Takeda Pharmaceutical Co Ltd’s (4502.T) $64 billion bid for London-listed rare disease specialist Shire Plc (SHP.L) bolsters its credentials as Japan’s most outward facing drugs firm, a mould-breaking image that has been more than a decade in the making. (3-0)

Takeda Announces Voluntary and Conditional Public Takeover Bid for Outstanding Shares, Warrants and American Depositary Shares of TiGenix NV to Commence April 30, 2018 | Business Wire

2018-04-25 businesswire
OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) today announced that the first acceptance period of its previously announced tender offer (the “Bid”) in cash for all outstanding ordinary shares (“Ordinary Shares”), warrants (“Warrants”) and American Depositary Shares (“ADSs”) of TiGenix NV (Euronext Brussels and NASDAQ: TIG) (“TiGenix”) that are not yet owned by Takeda and its affiliates, at an acquisition price of EUR 1.

UPDATED: Takeda Pharma and Shire Come Back to the Negotiating Table and Offer is Set at $64 Billion

2018-04-25 biospace
Takeda Pharmaceutical has come back with an improved bid for Shire for $64 billion, making it the fifth round of talks. Shire is willing to recommend to the board to accept the offer with an extended deal deadline of May 8. (5-0)



CUSIP: 88675R109